

HCP Engagement : Best Practices in the Age of Increasing Globalization, Regulation, and Data Privacy

Chris van Bronckhorst
Ben Carmel

15 May, 2019

Today's speakers



Ben Carmel

Global Head of Business Development
IQVIA Commercial Compliance

Contact information:

Email: benjamin.carmel@iqvia.com

Ben Carmel is IQVIA Commercial Compliance's subject matter expert for global transparency and HCP engagement technology solutions. Based in Boston Massachusetts, Ben oversees the go-to market team for IQVIA's Commercial Compliance group and has spent over fourteen years advising life sciences companies how to leverage consulting and technology solutions to streamline business processes and improve compliance.



Chris van Bronckhorst

Head of GTM, Europe & Asia
IQVIA Commercial Compliance

Contact Information:

Email: chris.vanbronckhorst@iqvia.com

Based out of Amsterdam, Chris van Bronckhorst leads IQVIA Commercial Compliance's business in Europe and the Asia-Pacific regions. Chris began his career as an IT systems developer. From this technical base, he developed over the course of a 22-year career as a manager and consultant in business strategy, program management, business transformation, IT systems implementations and organizational change.

Table of Contents

- + The Commercial Compliance landscape
- + Key elements for Commercial Compliance within MedTech
 - Fair Market Value
 - Engagement Management
 - Consent Management
 - Transparency Reporting
- + Where do we go from here?
- + Q&A

The Commercial Compliance Landscape

Multiple compliance risk areas

To be managed in collaboration with HCP/Os and life science industry



Anti-bribery /
Laundering



Off-label /
Disguised Promotion



Conflict of Interest



Data Privacy



Antitrust



Transparency



Local Requirements



Ethics, Image,
Reputation

What are your specific compliance obligations?

You have to manage both industry codes and country-specific requirements

MedTech Europe

- Phased out direct sponsorship for third-party events
- Transparency of educational grants
- Guidelines for interactions with HCPs (e.g. FMV)

AdvaMed : New Code of Ethics

- New code sections for marketing & education programs, communications, and technical support in a clinical setting
- Guidelines for interactions with HCPs (e.g. FMV)

Country Regulations

- Transparency Reporting Requirements - Portugal, France, Belgium




But challenges are broader

Compliance risk is only one element



No single, global view
of all engagements with
HCPs and HCOs



Insufficient compliance controls embedded
in the process



Multiple **handover points and manual work**,
leading to inefficiencies



Inconsistent **stakeholder experience**
(for HCPs/ HCOs)

MedTech companies need a single, global, scalable and efficient view of the customer, with integrated data sources and strategic analytics, delivering a streamlined, end-to-end solution, with built-in compliance controls.



**What new needs have arisen in
your organization from
expanding compliance
requirements?**

Balancing business demands & compliance obligations:



Companies are looking for **efficiency** to deploy resources to value-added activities



Obtaining **insight** from the data collected to enable strategic decision making



Faster decision making and turnaround times



Global solutions, integrated with existing platforms




Cost-effective solutions, configurable and low on support



Improved **customer relationships** with prescribers through digital engagement

Key elements for Commercial Compliance within MedTech

Key elements for commercial compliance within MedTech



Fair Market Value

Key elements of a successful methodology

Flexible

Ability to pay higher fees for higher degrees of expertise

Consistent

Simple model that allow for efficient application

Objective


Specific & measurable criteria for determining tier

Auditable

Maintain auditable records to support rate determination



Three levers of a practical FMV initiative




- **FMV rates should ensure that the value of a physician's time is compensated fairly, without bias based on the value of the service.**
- **While FMV rates based on objective data are a key control in the HCP engagement process they need to be supported by robust tiering models and consistent activity fee practice.**
 - Compensation data used for FMV represents national averages.
 - Industry does not routinely engage "average" physicians.
- **If you compensate based on tier, without a standard methodology it is difficult to ensure consistency.**
 - If you lack consistency, the control is **not** working.
 - Depending on your rate methodology the overpayment could be 20% - 80% depending on country and specialty.
- **FMV as a risk control is also strengthened if companies pay similar fees for similar activities based on standard service level expectations.**

Engagement management

Improves “ease of doing business” while strengthening internal compliance controls


Increase ease of doing business with HCP/O's

Streamline internal Engage to Pay Processes globally



End-to-end management for the complete engagement lifecycle

Process automation in HCP/O consulting, sponsorships and transparency reporting readiness





To what extent has your organization successfully operationalized the end-to-end process for HCP/O engagement and reporting?

If yes, how was this accomplished?

Global HCP engagement management

Case Study

BEFORE

- Growing reporting regulations
- Disconnected systems
- High cost of maintenance



AFTER

- Solved compliance requirements
- Single solution for transfers of value
- Increased IT efficiencies



Situation

- **Regulations and codes** regularly introduced or changed globally
- No **centralized or standardized** data systems in place
- Lack of a **single tracking process** for HCP engagement lifecycle
- **High IT costs** due to system complexity and lack of manageability

Solution

- Deployed a global interaction portal to **manage transfers of value**
- One portal provided **single sign-on** access to various systems
- **Improved data integrity** with one source of validated master records
- **Distributed relevant data** among customer's operational systems

Result

- Automated **compliance obligations** and **reduced risk exposure** globally
- Tracked, approved, and reported all **HCP and HCO transfers of value**
- Client now has a system that is: **Efficient, scalable, global** and provides **access to data and analytics**

Advanced functionality: data analytics

Using data to improve operational efficiency

Turn knowledge into actionable insights

Reports



Visibility into program activity, success measurement (utilization, ops, etc.) globally

Metrics



Turnaround times, provider satisfaction, spend metrics, historical measurement, most frequently used providers

Alerts



Alerts to improve the process: reminders to providers to submit receipts, bottleneck reports, compliance alerts, etc.



Expert Name	Cap Rule	Spend Limit	Spend Reserve	Total Actual Spend	Total Committed Spend	Total Spend	Cap Utilization % (Actual)	Cap Utilization % (Reserve)	Total Fee Engagements	Total Future Engagements	Total Cancelled Engagements
Aaron Edwards	Corporate Cap 2018	\$10,000	\$0	\$85,000.00	\$85,000.00	\$85,000.00	85%	85%	36	9	0
Robert Judd	Corporate Cap 2018	\$11,100	\$10,000	\$31,000.00	\$31,000.00	\$31,000.00	77%	85%	26	10	0
Greg Meyer	Corporate Cap 2018	\$14,000	\$0	\$27,000.00	\$44,000.00	\$17,000.00	62%	89%	27	5	0
Larry Gushers	Corporate Cap 2018	\$11,000	\$0	\$40,000.00	\$80,000.00	\$77,000.00	67%	67%	18	5	0
W. Paul Alexander	Corporate Cap 2018	\$75,000	\$0	\$45,000.00	\$39,375.00	\$75,000.00	60%	60%	35	9	0
Matthew Schuch	Corporate Cap 2018	\$75,000	\$0	\$75,000.00	\$0.00	\$75,000.00	100%	98%	27	0	0
Harrold Martin	Corporate Cap 2018	\$75,000	\$0	\$18,000.00	\$14,625.00	\$75,000.00	24%	98%	25	1	0
Guy Ford	Corporate Cap 2018	\$75,000	\$0	\$40,000.00	\$30,000.00	\$75,000.00	53%	57%	34	9	0
Wang Wu	Corporate Cap 2018	\$75,000	\$0	\$22,750.00	\$75,000.00	\$75,000.00	30%	98%	24	3	0
Paula Green	Corporate Cap 2018	\$75,000	\$0	\$80,000.00	\$71,000.00	\$71,000.00	93%	98%	16	0	0
Dr. Matthew	Corporate Cap 2018	\$75,000	\$0	\$10,000.00	\$11,750.00	\$75,000.00	13%	98%	25	4	0
Robert Sloan	Corporate Cap 2018	\$75,000	\$0	\$44,000.00	\$40,000.00	\$75,000.00	59%	94%	21	3	0
Paula Green	Corporate Cap 2018	\$75,000	\$0	\$17,500.00	\$15,000.00	\$75,000.00	23%	98%	26	2	0

HCP Name	Product	Topic	Attended	Attendance Cap
Aaron Edwards	Cardiovascular Product 1	Addressing Symptoms and Diagnosis	2	2
		Safety and Efficacy	2	2
		The Cardiovascular Continuum	2	2
	Modix	Modix Topic 1	2	2
		Modix Topic 2	2	2
Austin Sloan	Cardiovascular Product 1	Addressing Symptoms and Diagnosis	2	2
		Safety and Efficacy	2	2
		The Cardiovascular Continuum	2	2
	Modix	Modix Topic 1	2	2
		Modix Topic 2	2	2
Barbara Rantz	Cardiovascular Product 1	Addressing Symptoms and Diagnosis	2	2
		Safety and Efficacy	2	2
		The Cardiovascular Continuum	2	2
	Modix	Modix Topic 1	2	2
		Modix Topic 2	2	2
Carrie Parsons	Cardiovascular Product 1	Addressing Symptoms and Diagnosis	2	2
		Safety and Efficacy	2	2
		The Cardiovascular Continuum	2	2
	Modix	Modix Topic 1	2	2
		Modix Topic 2	2	2
Debra Ender	Cardiovascular Product 1	Addressing Symptoms and Diagnosis	2	2
		Safety and Efficacy	2	2
		The Cardiovascular Continuum	2	2
	Modix	Modix Topic 1	2	2
		Modix Topic 2	2	2
Glenn Berry	Cardiovascular Product 1	Addressing Symptoms and Diagnosis	2	2
		Safety and Efficacy	2	2
		The Cardiovascular Continuum	2	2
	Modix	Modix Topic 1	2	2
		Modix Topic 2	2	2



Advanced functionality: data driven decision making

Turn knowledge into actionable insights.

Remaining Budget



1. How much funding has been requested versus approved?

Success Measurement



3. How does funding look across countries for a single organization?

Program Overview



2. How is a department funding across different program types and therapeutic areas?

Historical Measurement



4. How does my funding look year-over-year?



**Do you believe that leveraging
compliance data for critical
business decisions is possible?**

Evolving commercial compliance technology

Clients are asking for a roadmap to implementing AI into the Engage platform



**Embedded
Intelligence in the
HCP Lifecycle**




**Reduce Overall
Cycle Time**



**Remove the Guesswork in
Meetings & Events Planning**



**Produce High
Quality and
Compliant
Outcomes**



**Make Data-Driven
Decisions and
Eliminate Bias**

The Smart Meetings Vision


Leverage technology to plan better events, which produce more a deeply engaged and informed community of healthcare professionals, leading to better treatment of patients and a healthier society.

Smart Meetings: Attendee management

Create meetings quickly to drive
maximum sales lift

Ada recommends the best:

- Venue based on past event success and ratings
- Speakers based on past events and speakers strengths
- Attendees based on attendance history (local and open payments) and predicted lift from attendance



Integrating privacy requirements with overall compliance controls

Protection of personal data under GDPR leads to operational complexity for companies



To meet GDPR requirements, companies must re-think their operational and technical processes and policies;
Core challenge: **How do we make GDPR controls a core part of our compliance programs?**



Above consent management, companies must prove their ability to store and manage personal data (including the right to be forgotten and thus the need to erase data)



Consent is also needed for transfers of values transparency purposes in some countries (HCPs consent for individual disclosure); **At the same time is consent the lawful basis for processing personal data?**



GDPR also requires compliance professionals to be involved in re-thinking the scope of their work and responsibilities

GDPR necessitates organizational change



DATA



Is the data we hold compliant?



COMPLIANCE



Can we demonstrate proof of consent?



PROCESSES



Are our processes efficient and reliable?



GOVERNANCE



Do we have mechanisms for continuous compliance across our IT ecosystem?



**How has your organization
managed this change?**

Key attributes of an optimized and automated process are changing



Direct HCP login through a specific, dedicated link



Ability to share HCP profile creating a simplified user experience—with key data managed in the system, with HCP consent.



Sales Rep or MSL ability to assist the HCP with the signing process



Confirmation guarantees the HCP identity, with voice message, text, or email validation.



Ad-hoc documents crafted to fit HCP needs with static or interactive templates



All signed documents automatically copied to the legal/compliance departments



Multi-language/Multi-country capabilities, including: Spanish, English, French, Italian, German, Polish, Portuguese, Dutch and Czech

Data privacy, consent collection, and management challenges solved

Case Study

What was the need?

- Undocumented consent to communicate
- Complex IT infrastructure with various types of consent
- Unable to quickly determine if consent was provided or guarantee personal data rights as required by GDPR

What was the outcome?

- Consent rate of 43% for targeted HCPs with trained call center staff, consistently yielding the best results
- GDPR compliance
- Fed consent status throughout the IT network = Unimpeded sales & marketing efforts

How was it addressed?

- Strategic multi-channel marketing campaigns for consent
- Online platform that manages all consent types
- Bi-directional integration with the customer master
- External facing portal allows HCPs to give/modify/revoke consent

And what should we consider further?

- Adaptability to future privacy and consent regulations
- How to be audit ready with a time-stamped digital audit trail

Where do we go from here?

How to get started

1. Establish Guidelines—
Are you solving
Transparency or HCP/O
Spend Automation or both?

**2. Establish Baseline
Collection Requirements**

4. Deployment Strategy

**3. Assessment in Each
Region / Global Group**

**5. Get To Work (Systems, Change
Management, Training, etc.)**

Sample of a cross regional engagement initiative

	Planning	Pre-Approval	Contracting	Payment & Reconciliation	Aggregation	Reporting	HCP/O Consent / Validation
Region/Country 1	As Is	☑	As Is	☑	☑	☑	N/A
Region/Country 2	As Is	☑	As Is	As Is	As Is	☑	As Is
Region/Country 3	☑	☑	☑	☑	TBD	☑	TBD

Illustrative

Deployment strategies – best practices



Fixed Duration Pilot

- Region, Transaction Type, Expedited SDLC, Key Stakeholders, Rapid Prototyping



Allows for Proof of Concept



Requirements Tend to Change During Long Projects Anyway



Consider Cross-Border and Other Global Groups First



Implement Foundational Technology (MDM, ERP, CRM, etc.)

Key takeaways



Many companies overlook the end-to-end HCP/O engagement process



Building a robust engagement process can unlock business value and improve relationships with HCP/Os



Consider establishing a cross functional Global Engagement team



Ensure you are not forgetting foundational HCP processes, such as FMV



Build data privacy requirements into systems from day one, even if you see no additional business benefit



Don't overcomplicate – focus on gaps and phased roll-outs, don't try to build it all day-one



Don't underestimate change management aspects



Make sure to coordinate with existing/pending compliance programs (ABAC/FCPA, transparency)



Q & A

Disclaimer

The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third party sources or data.

As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks and uncertainties, and are not to be considered guarantees of any particular outcome.

All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of IQVIA.

Copyright © 2019 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.

Thank you.

2019 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited

2019 © The MedTech Forum. All rights reserved - Reproduction in whole or in part is prohibited